powered by centersite dot net
Medications
Resources
Basic InformationLatest News
New Cholesterol Drugs Vastly Overpriced, Study ContendsFDA May Limit 'Risk Info' in Direct-to-Consumer TV Drug AdsHealth Tip: Throwing Out Leftover MedicineFDA Announces Recall of Some Liquid Pharmaceutical ProductsIs FDA Taking Close Enough Look at Fast-Tracked Drugs?U.S. Antidepressant Use Jumps 65 Percent in 15 YearsThe Fine Print on Medication Expiration DatesAmericans Taking More Prescription Drugs Than Ever: SurveyInappropriate Med Use High in Cognitively Impaired SeniorsA Reminder That Meds and Grapefruit Don't Always MixAspirin Responsiveness Can Change After Bariatric SurgerySome Medicines Boost Sensitivity to SunPainkiller Prescriptions More Prone to Errors If HandwrittenMedication Mistakes Have Doubled in U.S. Since 2000: StudyMarket Competition Linked to Change in Generic Drug PricesIs Your Child's 'Penicillin Allergy' Real?FDA Seeks to Increase Number of Generic Drugs on MarketWhen Is an Opioid Safe to Take?Lifesaving Drugs From Pfizer in Short Supply: FDALeading U.S. Doctors' Group Takes Aim at Rising Drug PricesU.S. Hospitals Still Prescribe Too Many Antibiotics: StudyBirth Control Pills Recalled Due to Danger of Unintended PregnancyNew Drugs Show Promise as First to Prevent MigraineMedication Adherence Up With Refill Synchronization ModelModified Vancomycin May Help Fight Bacterial ResistanceScientists Tweak Antibiotic to Boost Power Against 'Superbugs'New Cholesterol Fighting Meds Target Key GeneResearchers Say PDE5 Inhibitors Don't Cause MelanomaNearly a Third of Drugs Hit by Safety Issues After FDA ApprovalU.S. Moves to Avert Shortage of Yellow Fever VaccineOpioid Use by Iraq, Afghanistan War Vets Mirrors Rest of U.S.: StudyApril 29 Is National Prescription Drug Take Back DayERs Administering More Medications IntranasallyFDA Warns Against Children Taking Codeine, TramadolPhysicians Finding Ways to Work Around Cost of Rx MedicationsRuling Out Penicillin Allergy by Testing Inpatients Saves MoneyEpiPen Out-of-Pocket Costs More Than Doubled Over DecadeAACR: Regular Aspirin Use Linked to Lower Cancer MortalityFDA Approves Noctiva Nasal Spray for Nocturnal PolyuriaFDA Approves Odactra for House Dust Mite AllergiesHow Much Melatonin Is Really in That Supplement?Antidepressant Efficacy Varies for Depressive Symptom ClustersDo You Need an Antibiotic?'Off-Label' Antidepressants Common, But Where's the Evidence?Docs More Likely to Prescribe Antibiotics If Patients Expect ThemSimilar Adverse Event Risk for Typical, Atypical AntipsychoticsRx Adherence Reminders No More Effective at 'Fresh Start' DatesThink You're Allergic to Penicillin? Check AgainExcessive FDA Regulation Driving High Drug PricesOutcomes-Based Pricing Suggested for New, Costly Drugs
Questions and AnswersVideosLinksBook Reviews
Related Topics

Anxiety Disorders
Depression: Depression & Related Conditions
Mental Disorders
Mental Health Professions

Steep Rise in U.S. Drug Prices Tied to Patent Monopolies


HealthDay News
Updated: Aug 24th 2016

new article illustration

WEDNESDAY, Aug. 24, 2016 (HealthDay News) -- Prescription drug prices are skyrocketing in the United States due in large part to government regulations, according to a study published in the Aug. 23/30 issue of the Journal of the American Medical Association.

The current government regulations allow drug manufacturers to charge monopolistic prices that aren't opposed by competing market forces, the researchers believe. Between 2013 and 2015, net spending on prescription drug prices increased about 20 percent in the United States, outpacing a forecast 11 percent increase on all health care costs combined, the authors said in background notes.

For each person in the United States in 2013, $858 was spent on prescription drugs, compared with an average of $400 per person across 19 other industrialized nations. Prescription medications now comprise an estimated 17 percent of overall health care expenses, the authors of the report said.

"The most realistic short-term strategies to address high prices include enforcing more stringent requirements for the award and extension of exclusivity rights; enhancing competition by ensuring timely generic drug availability; providing greater opportunities for meaningful price negotiation by governmental payers; generating more evidence about comparative cost-effectiveness of therapeutic alternatives; and more effectively educating patients, prescribers, payers, and policy makers about these choices," the authors write.

Abstract
Full Text